论文部分内容阅读
目的评价雷利度胺对自体造血干细胞移植(AHSCT)后复发难治性套细胞淋巴瘤的疗效。方法回顾性分析浙江中医药大学附属第一医院血液科收治的1例行AHSCT后2次复发套细胞淋巴瘤患者的临床资料和治疗经过。先后应用雷利度胺联合地塞米松以及雷利度胺联合COD方案(环磷酰胺、长春瑞滨和地塞米松)治疗,并结合文献进行分析讨论。结果患者经以雷利度胺为主方案治疗后,疾病再次获得完全缓解,截至2015年11月初已经随访6个月,疾病未见复发。结论雷利度胺对复发难治性套细胞淋巴瘤有良好的治疗效果,可以作为AHSCT后复发套细胞淋巴瘤患者有效的治疗手段。
Objective To evaluate the efficacy of lenalidomide in refractory mantle cell lymphoma after autologous hematopoietic stem cell transplantation (AHSCT). Methods The clinical data and treatment of 2 patients with recurrent MCDCL after 1 AHSCT were retrospectively analyzed in Department of Hematology, the First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine. The application of lenalidomide in combination with dexamethasone and lenalidomide in combination with COD regimen (cyclophosphamide, vinorelbine and dexamethasone), followed by literature analysis and discussion. Results After the patient was treated with lenalidomide as the main regimen, the disease was completely relieved again. As of the beginning of November 2015, it was followed up for 6 months and the disease did not recur. Conclusions Lenalidomide has a good curative effect on refractory mantle cell lymphoma and can be used as an effective treatment for patients with recurrent mantle cell lymphoma after AHSCT.